Share:
Letter

Dermoscopic findings of perifollicular pigmentation associated with vandetanib

Author Affiliation(s)

Introduction

Vandetanib is an oral tyrosine kinase inhibitor used in the treatment of different types of cancer. It acts by inhibiting the vascular and epidermal growth factor receptor and is associated with frequent adverse cutaneous reactions such as acneiform eruption, photosensitivity, pigmentary changes, exanthema, pruritus, and xerosis. We describe an unusual, peculiar form of perifollicular pigmentation associated with the use of the drug and show its dermoscopic findings.

Case Presentation

A 26-year-old male patient was diagnosed with metastatic medullary thyroid carcinoma. After combined treatment with surgery, radiotherapy, and chemotherapy, the disease progressed and vandetanib was started. Two weeks later, the patient developed an acneiform rash with lesions on the trunk and face and was subsequently treated with doxycycline 200 mg/day for 6 months with improvement. On dermatological follow-up, the patient was still taking vandetanib, with clearance of the acneiform lesions, but many pigmented follicular macules with a comedo-like appearance were noted on the face and chest ( Figure 1 ). The pigmentation was apparently follicular; however, on dermoscopy, the blue-gray pigment was evident only in the perifollicular area with preservation of the center of the hair follicle ( Figure 2 ). After orienting the patient on photoprotective measures, only a little improvement was noted. One year later, the patient had complete clearing, despite the continuous use of vandetanib.

Figure 1.

Pigmented follicular macules with comedo-like appearance on the face. [Copyright: ©2018 Cury-Martins et al.]

Figure 2.

On dermoscopy, the blue-gray pigment is evident only on the perifollicular area. [Copyright: ©2018 Cury-Martins et al.]

Discussion

Among the pigmentary changes associated with vandetanib therapy, diffuse pigmentation in the exposed area is the most reported form. The blue-gray perifollicular pigmentation was rarely reported, and there are no similar reports of it with other agents of the same class. This seems to be specifically caused by this medication.

The pathogenesis of this peculiar pattern of pigmentation is not well established. Previous reports have demonstrated the histopathological alterations in a few similar cases revealing dermal iron and melanin deposition. The presence of pigmented macrophages and inflammatory infiltrate in the dermis was also documented [ 1 ]. Those findings correlate with the dermoscopy, with the blue-gray pigmentation corresponding to the presence of dermal pigment.

The previous use of doxycycline did not seem to factor into the etiology of this condition. Giacchero et al [ 2 ] showed that less than half of the patients in their series were treated with this medication. Prior photosensitivity preceding the pigmentation was described in two cases [ 1 ].

Definitive treatment of the lesions involves stopping the use of vandetanib followed by improvement after 3–6 months. However, recurrence occurs if the medication is reintroduced [ 2 ]. The use of topical depigmentation agents such as the combination of hydroquinone, tretinoin, and corticosteroids did not show benefits [ 1 ]. In a few cases, the use of photoprotective measures prevented worsening of the condition, [ 1 ].

Conclusion

In conclusion, we report the first description of dermoscopic findings of this rare pattern of perifollicular pigmentation associated with vandetanib use. As oncodermatology is involved in the supportive care of cancer patients, it is important for dermatologists to identify these possible adverse events and use dermoscopy as an additional tool.

References

  1. Cutaneous pigmentation following photosensitivity induced by vandetanib Kong HH, Fine HA, Stern JB, Turner MLC. Arch Dermatol.2009;145(8):923-925.
  2. New spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib Giacchero D, Ramacciotti C, Arnault JP, et al. Arch Dermatol.2012;148(12):1418-1420.

Send mail to Author


Send Cancel